Aclaris Therapeutics, Inc. (ACRS) NASDAQ

4.63

+0.29(+6.68%)

Updated at June 02 04:00PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Neal S. Walker	Co-Founder, Chief Executive Officer & Chairman	965,550	1970
Jesse W. Hall	Chief Medical Officer	371,166	1974
Roland Kolbeck	Chief Scientific Officer	492,432	1964
Hugh Davis	President, Chief Operating Officer & Director	555,541	1960
James Loerop	Chief Business Officer	590,160	1965
Kevin Balthaser	Chief Financial Officer	631,710	1987
Jon Jacobsen	Senior Vice President of Chemistry	0	N/A
Ajay Aggarwal	Senior Vice President of Clinical Development	0	N/A
Matthew Rothman	General Counsel & Corporate Secretary	0	N/A
Shaun Selness	Senior VP, Head of Discovery & Preclinical Sciences	0	N/A
Steve Tucker	Executive Vice President of Project Leadership	0	N/A
William C. Roberts	Senior Vice President of Corporate Communications & Investor Relations	0	1969
Meghan Dunsmore	Senior Vice President of Finance	0	N/A
Nina Samra	Senior Vice President of Clinical Operations	0	N/A

Name

Title

Pay

Year Born

Neal S. Walker

Co-Founder, Chief Executive Officer & Chairman

965,550

1970

Jesse W. Hall

Chief Medical Officer

371,166

1974

Roland Kolbeck

Chief Scientific Officer

492,432

1964

Hugh Davis

President, Chief Operating Officer & Director

555,541

1960

James Loerop

Chief Business Officer

590,160

1965

Kevin Balthaser

Chief Financial Officer

631,710

1987

Jon Jacobsen

Senior Vice President of Chemistry

N/A

Ajay Aggarwal

Senior Vice President of Clinical Development

N/A

Matthew Rothman

General Counsel & Corporate Secretary

N/A

Shaun Selness

Senior VP, Head of Discovery & Preclinical Sciences

N/A

Steve Tucker

Executive Vice President of Project Leadership

N/A

William C. Roberts

Senior Vice President of Corporate Communications & Investor Relations

1969

Meghan Dunsmore

Senior Vice President of Finance

N/A

Nina Samra

Senior Vice President of Clinical Operations

N/A

Description

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.